Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]
News [4942]
Articles [204]
Editorials [8]
Conferences [138]
elearning [14]
The future of Choosing Wisely Africa
Dr Fidel Rubagumya - Queen's University, Canadá / University of Rwanda, Kigali...
The future of Choosing Wisely Africa ( Dr Fidel Rubagumya - Queen's University, Canadá / University of Rwanda, Kigali, Rwanda )
21 Dec 2023
Zanidatamab, palbociclib and fulvestrant show positive results in treating...
Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO)...
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )
20 Dec 2023
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2...
Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )
20 Dec 2023
Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...
Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany
Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )
20 Dec 2023
Beat AML master trial: A clinical trial for acute myeloid leukaemia
Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Beat AML master trial: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
20 Dec 2023
BrECADD combined with PET2-guided treatment sets a new benchmark for the...
Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany
BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL ( Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany )
19 Dec 2023
The evolving paradigm in management of Multiple Myeloma
Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
The evolving paradigm in management of Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
11 Dec 2023
Introducing oncology to undergraduate medical and allied health sciences...
Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India
Introducing oncology to undergraduate medical and allied health sciences students ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )
8 Dec 2023
Low-dose olanzapine after highly emetogenic chemotherapy can be the new...
Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )
7 Dec 2023
Relapsed refractory multiple myeloma
Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023
Special issue on real world breast cancer data
Dr Siddhartha Kar - University of Cambridge, Cambridge, UK
Special issue on real world breast cancer data ( Dr Siddhartha Kar - University of Cambridge, Cambridge, UK )
21 Nov 2023
Trial investigates multiparametric prognostic score in early HR+/HER2- breast...
Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany
Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )
21 Nov 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation